Synthetic cannabinoid use disorder: an update for general psychiatrists.
Australas Psychiatry
; 27(3): 279-283, 2019 06.
Article
en En
| MEDLINE
| ID: mdl-30663326
ABSTRACT
OBJECTIVE:
Synthetic cannabinoid use disorder is emerging as a significant clinical issue. This article provides the general psychiatrist with an overview of the physical and psychiatric adverse effects of chronic synthetic cannabinoid use, as well as specific clinical responses.METHOD:
We performed electronic searches of Ovid MEDLINE and Ovid Embase to identify key articles, of all methodological designs, published up to June 2018.RESULTS:
The available evidence suggests that, compared to cannabis, use of synthetic cannabinoids is associated with the more rapid development of dependence, increased psychiatric risks and complex withdrawal, and serious physical adverse effects that include seizures, cardiotoxicity and death, denoting a potential need for more intensive management.CONCLUSION:
When synthetic cannabinoid use is identified, along with management of acute physical and psychiatric adverse effects, psychotherapeutic strategies to reduce use and/or harm are recommended.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Contexto en salud:
2_ODS3
/
8_ODS3_consumo_sustancias_psicoactivas
Problema de salud:
2_sustancias_psicoativas
/
8_cannabis_related_disorders
/
8_cocaine_other_stimulant_related_disorders
Asunto principal:
Cannabinoides
/
Abuso de Marihuana
/
Drogas Sintéticas
Tipo de estudio:
Systematic_reviews
Límite:
Humans
Idioma:
En
Revista:
Australas Psychiatry
Asunto de la revista:
PSIQUIATRIA
Año:
2019
Tipo del documento:
Article
País de afiliación:
Australia